Oral / Subcutaneous · GLP-1 / GIP dual
HRS9531
38 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
38
Ongoing
21
Recruiting
8
Completed
16
Sites
169
Countries
6
Endpoints
480
Composite endpoints
13
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
15
Phase 2
11
Phase 3
12
Trials by status
Not yet recruiting
8
By invitation
1
Recruiting
8
Active, not recruiting
4
Completed
16
Unknown
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
163
Weight & body composition
106
Cardiometabolic biomarkers
60
Glycemic / diabetes
58
Patient-reported / QoL
33
Other clinical outcomes
19
Other (unclassified)
11
Cardiovascular outcomes
9
Heart failure
9
MASH / liver
6
Renal / kidney
6
Top 20 metrics across this asset's endpoints
Treatment-emergent AEs (any)Safety/PK
30
AUC₀-∞Safety/PK
29
Body weight, % changeWeight
21
Body weight, absolute change (kg)Weight
21
Fasting glucose, changeGlycemic
20
TmaxSafety/PK
19
Immunogenicity (ADA)Safety/PK
18
CmaxSafety/PK
16
HbA1c, changeGlycemic
14
Waist circumference, changeWeight
13
BMI, changeWeight
12
≥5% weight-loss respondersWeight
10
Half-lifeSafety/PK
9
Total cholesterol, changeBiomarker
9
≥10% weight-loss respondersWeight
7
Triglycerides, changeBiomarker
7
HbA1c <7.0% achievementGlycemic
6
AHI, changeOther clin.
6
HDL-C, changeBiomarker
6
LDL-C, changeBiomarker
5
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
38 of 38
Showing 1-25 of 38 trials